A post hoc analysis of data from the Mainsail study has shown that treatment with eight or more cycles of docetaxel is associated with improved overall survival rates in men with prostate cancer. Patients involved in the Mainsail study received either docetaxel, prednisone and lenalidomide or docetaxel, prednisone and placebo; however, men in the lenalidomide arm received fewer cycles of docetaxel owing to the toxic effects of the combination treatment. Irrespective of whether lenalidomide was part of their treatment regime, men who underwent more cycles of docetaxel had significantly superior overall survival.
References
de Morrée, E. S. et al. Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered a post hoc analysis of the Mainsail study. JAMA Oncol. http://dx.doi.org/10.1001/jamaoncol.2016.3000 (2016)
Rights and permissions
About this article
Cite this article
Stone, L. More cycles of docetaxel improve survival. Nat Rev Urol 13, 566 (2016). https://doi.org/10.1038/nrurol.2016.181
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.181